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Background: The aim of this study was to determine whether long-term intermittent   azithromycin 
therapy reduces the frequency of exacerbation in severe chronic obstructive pulmonary 
disease (COPD).
Methods: We retrospectively investigated the clinical benefits of long-term azithromycin 
(500 mg orally three times per week) over 12 months in patients with severe COPD and a 
minimum of four acute exacerbations (AECOPD) per year or chronic bronchial colonization by 
Pseudomonas aeruginosa, comparing the number of AECOPD, hospitalizations due to respira-
tory disease, days of hospital stay, and bacterial infections during azithromycin treatment and 
in the year prior to this therapy.
Results: Twenty patients who completed the 12-month treatment period were analyzed. No 
clinically significant adverse events were observed during azithromycin treatment. Compared 
with baseline data, azithromycin therapy significantly reduced the number of AECOPD (2.8 ± 2.5 
versus 6.8 ± 2.8, P , 0.001), hospitalizations (1.4 ± 1.5 versus 3.6 ± 1.4, P , 0.001), and cumula-
tive annual days of hospital stay (25 ± 32.2 versus 43.7 ± 21.4, P = 0.01). The improvement was 
particularly significant in patients with exacerbations caused by common potentially pathogenic 
microorganisms, who had 70% fewer AECOPD and hospitalizations. Patients colonized by 
P . aeruginosa had reductions of 43% in AECOPD and 47% in hospitalizations.
Conclusion: Long-term azithromycin is well tolerated and associated with significant reductions 
in AECOPD, hospitalizations, and length of hospital stay in patients with severe COPD.
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Introduction
Acute exacerbations of chronic obstructive pulmonary disease (COPD) are a fre-
quent event during evolution of the disease,1 and the mortality risk increases with its 
frequency, especially when patients require hospitalization.2,3 Previous studies using 
protected specimen brushing have shown that bacterial infection could be the etiol-
ogy in approximately 50% of acute exacerbations of COPD (AECOPD).4 However, it 
is sometimes difficult to distinguish colonization from infection when organisms are 
found in sputum cultures from COPD patients.
Recently, interest in the use of prophylactic antibiotics to prevent AECOPD has 
increased,5 and macrolides in this setting have the advantage of having both antibacte-
rial and anti-inflammatory properties. Long-term macrolide therapy is routinely used 
in two diseases, ie, diffuse panbronchiolitis and cystic fibrosis, both of which involve 
chronic airway inflammation. Erythromycin is the most commonly used macrolide in 
diffuse panbronchiolitis, and obtains notable improvements in symptoms and   survival.6 International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Studies in cystic fibrosis have mostly used azithromycin and 
have found improvement in lung function and a reduced 
exacerbation frequency.7,8 These effects are probably due to 
modulation of the inflammatory response and its ability to 
impede formation of biofilm.9 Azithromycin has also been 
shown to be useful in the treatment of patients with bron-
chiectasis and chronic bronchial infection by Pseudomonas 
aeruginosa.10,11
Given the importance of inflammation12 and bacterial 
infection in the pathogenesis of COPD, it has been proposed 
that macrolides may offer unique advantages as disease-
modifying agents. Only two studies to date have analyzed 
the effectiveness and safety of long-term erythromycin in 
COPD over a 12-month period, reporting a significant reduc-
tion in moderate to severe AECOPD.13,14 It remains to be 
established whether the therapeutic effect of erythromycin 
reflects antimicrobial activity, an immunomodulatory effect, 
or both. Preliminary data have recently been reported for the 
MACRO study, a randomized controlled trial evaluating the 
utility of long-term azithromycin therapy to reduce AECOPD, 
with promising results.15 Compared with erythromycin, 
the prototypical 15 member-ring macrolide, azithromycin, 
appears to have a better safety profile in long-term use, as 
well as improved bacteriological activity.16
In this study, we investigated: the usefulness of long-term 
intermittent azithromycin therapy in reducing exacerbation 
frequency in severe COPD patients at a high risk of AECOPD 
despite conventional maximum treatment; its impact on the 
bacteriology of bronchial secretions, examining baseline and 
follow-up colonization by P . aeruginosa or other potentially 
pathogenic microorganisms; and its impact on the develop-
ment of resistance to macrolides.
Materials and methods
subjects
We identified a cohort of 203 patients with severe COPD, 
with a postbronchodilator forced expiratory volume in one 
second (FEV1) ,50% of predicted and routinely controlled 
at the respiratory day care unit of the Sabadell Hospital in 
Barcelona, Spain, between March 2007 and August 2009. 
Patients with chronic bronchitis who had repeated AECOPD 
(at least four exacerbations in the previous year) or chronic 
bronchial colonization by P . aeruginosa treated with long-
term azithromycin therapy were recruited for this study. 
Patients with asthma, significant bronchiectasis, malignancy, 
unstable heart disease, or liver disease were excluded.   Ethical 
permission for the study was obtained from the Sabadell 
Hospital ethics committee.
study design
Retrospective analysis of data for the year before initiation of 
long-term azithromycin therapy (for 12 months) in patients 
with severe COPD was undertaken in order to assess the clini-
cal benefits of this treatment to reduce AECOPD frequency. 
Azithromycin (one 500 mg tablet) was administered three 
times per week (Monday, Wednesday, Friday), in accordance 
with standard practice in patients with bronchiectasis associ-
ated with cystic fibrosis and chronic bronchial colonization 
by P . aeruginosa.17
Patients were classified into three groups according to 
the potentially pathogenic microorganisms isolated from 
their sputum samples during AECOPD in the year prior 
to azithromycin therapy, ie: Group 1, patients with at least 
two positive cultures for common potentially pathogenic 
microorganisms (Haemophilus influenzae, Streptococcus 
pneumoniae, Moraxella catarrhalis); Group 2, patients 
with chronic bronchial colonization by P . aeruginosa 
(at least three consecutive sputum cultures for potentially 
pathogenic microorganisms during a 6-month period of 
stability);18 and Group 3, patients whose cultures alter-
nated between being positive for common potentially 
pathogenic microorganisms and P . aeruginosa during 
exacerbations but without chronic bronchial colonization 
by this bacteria.
We compared the following parameters overall and by 
group before and after the 12-month azithromycin treatment 
period: number of registered AECOPD; number of hospi-
talizations due to respiratory disease; and length of hospital 
stay. We also traced the evolution of positive cultures for 
potentially pathogenic microorganisms during AECOPD in 
each group and the development of resistance to azithromycin 
before and after long-term therapy.
All patients underwent the same scheduled clinical 
assessments at the respiratory day care unit19 by the same 
team of pulmonologists before and after starting long-term 
azithromycin therapy. At baseline, pulmonary function tests 
and use of home oxygen therapy were recorded. A high-
resolution computed tomography of the chest was performed 
in all patients in a stable state to assess and quantify possible 
bronchiectasis. Monitoring visits were conducted every 
3 months during the 2 years of study.
Number of registered AECOPD, hospitalizations due 
to respiratory disease, length of hospital stays, and micro-
biological isolates in the previous 12 months were recorded 
just before the initiation of azithromycin therapy and 1 year 
later. A sputum sample was routinely collected during each 
AECOPD. All patients received regular treatment with International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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long-acting beta-agonists, long-acting anticholinergics, and 
inhaled corticosteroids during the 2 years of study.
When used in patients with chronic P . aeruginosa 
colonization, inhaled colimycin therapy was maintained 
during the full length of the study and recorded. During 
follow-up, an electrocardiogram, liver and renal function test, 
and complete blood count measurements were performed 
before and after initiation of azithromycin treatment. The 
appearance of possible adverse events was assessed at each 
monitoring visit.
Assessment of bronchiectasis
Bronchiectasis in the high-resolution computed tomogra-
phy scan was scored in each lobe by consensus, using the 
grading system proposed by Smith et al20 as follows: 0 if 
no bronchiectasis was present, 1 if ,25% of bronchi were 
bronchiectatic, 2 if 2%–49% bronchi were bronchiectatic, 3 
if 50%–74% bronchi were bronchiectatic, and 4 if $75% of 
the bronchi were bronchiectatic. The lingula was graded as a 
separate lobe, resulting in a maximum score of 24 per patient. 
Patients with a score #1 were considered normal.
Definition and treatment of exacerbations
AECOPD was defined as a sustained worsening of the 
patient’s condition from the stable state and beyond normal 
day-to-day variations, of acute onset, and requiring a change 
in regular treatment (oral corticosteroids and/or antibiot-
ics and/or hospital admission) in a patient with underlying 
COPD.21
A chest radiography was performed for each AECOPD 
to exclude acute pneumonia. AECOPD were attended from 
Monday to Friday (8 am to 5 pm) at the respiratory day care 
unit, always by the same team of pulmonologists.19 Outside 
these hours, AECOPD were attended at the emergency 
department and registered by reviewing the emergency 
reports.
Antibiotics were prescribed during AECOPD according 
to Anthonisen’s criteria and were adjusted by antibiogram, 
maintaining azithromycin at the same dose.22 Indications of 
hospital admission were made according to clinical practice 
guidelines.23
Bacteriological assessments
Sputum samples were collected from all patients for each 
AECOPD and were processed locally for Gram stain and 
bacteriological culture. Identification and antibiogram 
were performed on all bacterial isolates following stan-
dardized microbiological protocols.24 Positive cultures for 
P . aeruginosa during AECOPD were followed by   performing 
additional sputum cultures at every follow-up visit to iden-
tify chronic colonization, diagnosed when three or more 
consecutive sputum cultures for this potentially pathogenic 
microorganism were found over a period of 6 months in 
clinically stable patients, in samples separated by at least 
1 month.18
statistical analysis
All the information was entered into a database and analyzed 
using SPSS version 17 (SPSS Inc, Chicago, IL). Quantitative 
variables are expressed as mean ± standard deviation, and 
categorical variables as absolute and relative frequencies. 
The frequency and length of exacerbations and the microbi-
ology of the sputum cultures before and after azithromycin 
treatment were compared. Statistical analysis was performed 
using the Student’s t-test for paired data and Chi-square 
tests as required. All statistical tests were performed with a 
confidence level of 95%.
Results
Twenty-four eligible patients with severe COPD and fre-
quent AECOPD from the cohort of 203 patients controlled 
at the respiratory day care unit agreed to participate in this 
study. Baseline variables for the long-term azithromycin 
treatment group are shown in Table 1. Ten of 24 patients 
(41.6%) had no detectable bronchiectasis on   high-resolution 
Table 1 Baseline variables of the first year of follow-up for the 
long-term azithromycin therapy group
Baseline variables 
(year 1 of follow-up)
Mean 
(SD)
Age (years) 70.9 (7.4)
FeV1, L 0.9 (0.2)
FeV1, %predicted 32.2 (9.3)
FVC (L) 2.4 (0.5)
FeV1/FVC (%) 39.6 (9.6)
number of AeCOPD/previous year 7.0 (3.0)
number of hospitalization/previous year 3.3 (2.0)
Days of hospital stay/previous year 43.0 (26.2)
n (%)
Very severe COPD (gOLD IV) 11 (46)
Chronic bronchitis 24 (100)
Current smoker 0 (0)
Male 24 (100)
Chronic oxygen therapy 5 (20.8)
Pseudomonas aeruginosa colonization 9 (37.5)
Abbreviations: COPD, chronic obstructive pulmonary disease; AeCOPD, acute 
exacerbation of chronic obstructive pulmonary disease; FeV1, forced expiratory 
volume  in  one  second;  FVC,  forced  vital  capacity;  gOLD,  global  Initiative  for 
Chronic Obstructive Lung Disease; sD, standard deviation.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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computed tomography. The median ± standard deviation of 
total   bronchiectasis score20 was 3.3 ± 3.5 (range 0–9).
After initiation of azithromycin, four patients did not 
complete the scheduled 12-month antibiotic treatment period. 
One was withdrawn for mild dyspepsia, one because of a 
diagnosis of malignancy during follow-up, and the other two 
discontinued the treatment prematurely as a personal deci-
sion in the absence of reported side effects. No significant 
adverse events were observed among the 20 patients who 
completed the 12-month treatment period. One patient died 
in hospital as a result of an AECOPD during the last month 
of follow-up. These 20 patients comprised the sample for 
the comparative study.
In the 12 months prior to the start of azithromycin, the 
20 study participants had a total of 136 AECOPD, of which 72 
(52.9%) were severe and required hospitalization.   Long-term 
azithromycin therapy achieved statistically significant reduc-
tions in AECOPD from 136 to 57 (a 58.9% decrease) and 
hospitalizations from 72 to 28 (a 61.2% decrease) and a 
reduction of 18.7 days in yearly mean hospital stay due to 
respiratory disease (see Table 2).
On the basis of potentially pathogenic microorgan-
isms isolated in sputum samples during the year prior 
to starting azithromycin, seven patients with common 
potentially pathogenic microorganisms were included in 
Group 1, nine patients with chronic bronchial colonization 
by P .   aeruginosa in Group 2 (of whom five [55.5%] were 
receiving inhaled colimycin therapy), and four patients 
with exacerbations due to common microorganisms and 
P . aeruginosa in Group 3. Long-term azithromycin therapy 
reduced the number of AECOPD, hospitalizations, and 
days of hospital stay in all groups. This reduction was 
particularly significant in Group 1 (common potentially 
pathogenic microorganisms) with a 70% reduction in 
AECOPD and hospitalizations, and a mean reduction of 
25 days in mean hospital stay. In the group colonized 
by P .   aeruginosa, a statistically significant reduction in 
AECOPD of 43.5% was observed, the number of hos-
pitalizations fell by 47.1%, and their hospital stays by 
32.5%, although these differences did not reach statisti-
cal   significance. The group alternating between common 
potentially pathogenic microorganisms and P .   aeruginosa 
during exacerbations showed improvements in all param-
eters studied, but no statistical comparisons were per-
formed because of their small sample size (see Table 2 and 
Figure 1). AECOPD with sputum cultures isolating only 
common potentially pathogenic microorganisms fell from 
31 of an overall 136 (22.7%) to five of 57 (8.7%) during 
long-term azithromycin therapy (P , 0.05).
Long-term azithromycin therapy rendered sputum 
cultures negative during AECOPD in nine of 20 patients 
during follow-up, including four from the common poten-
tially pathogenic microorganism group, four from the 
P . aeruginosa colonization group (without any significant 
association with the presence of mucoid forms or inhaled 
colimycin therapy, data not shown), and one from the 
common potentially pathogenic P . aeruginosa group. 
Table 3 shows the microbiological evolution of patients 
Table 2 number of AeCOPD, hospitalizations due to respiratory disease, and days of hospitalization with and without azithromycin,   
overall and according to the group of potentially pathogenic microorganisms isolated from sputum samples before initiation of azithromycin
Variable 
Overall 
(n = 20)
0–12 months 
without azithromycin
12–24 months 
with azithromycin
% Red P
Total Mean ± SD Total Mean ± SD
exacerbations (n) 136 6.8 ± 2.8 57 2.8 ± 2.5 58.9 0.000
hospitalizations (n) 72 3.6 ± 1.9 28 1.4 ± 1.5 61.2 0.001
hospital stay (days) 874 43.7 ± 21.4 500 25.0 ± 32.2 42.8 0.013
Common PPM group 
(n = 7)
exacerbations (n) 63 9.0 ± 2.3 19 2.7 ± 2.2 70 0.00
hospitalizations (n) 29 4.1 ± 2.6 9 1.2 ± 1.4 70.8 0.04
hospital stay (days) 309 44.1 ± 17.5 133 19 ± 25 57 0.05
Pseudomonas aeruginosa group 
(n = 9)
exacerbations (n) 42 4.6 ± 2.2 24 2.6 ± 2.0 43.5 0.04
hospitalizations (n) 31 3.4 ± 1.6 17 1.8 ± 1.7 47.1 0.08
hospital stay (days) 454 50.4 ± 23.9 306 34.0 ± 38.5 32.5 0.23
Abbreviations: AeCOPD,  acute  exacerbation  of  chronic  obstructive  pulmonary  disease;  PPM,  potentially  pathogenic  microorganisms;  sD,  standard  deviation;   
% red, percentage reduction.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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during azithromycin treatment in relation to sputum cultures 
obtained during the first year.
Table 4 shows the sensitivity of common potentially 
pathogenic microorganisms to macrolides before and after 
long-term azithromycin therapy. Interestingly, all strains of 
H. influenzae isolated were resistant to erythromycin and 30% 
to clarithromycin, while none were resistant to azithromycin 
prior to treatment. The macrolide-resistant S. pneumoniae 
strains were also resistant to clindamycin, representing a 
highly resistant phenotype.
On assessment of the bactericidal effect of long-term 
azithromycin therapy on common potentially patho-
genic microorganisms and the development of bacterial 
resistance, we found no isolates of M. catarrhalis with 
azithromycin resistance during follow-up, a single isolate 
of H. influenzae with resistance to the antibiotic, and four 
isolates of S. pneumoniae, all resistant to azithromycin. 
The prevalence of resistance did not show statistically 
significant differences from the figures found in the first 
year of the study.
Discussion
This is the first study to examine long-term intermittent azithro-
mycin therapy over a 12-month period in patients with severe 
COPD and repeated AECOPD, or chronically colonized by P.  
aeruginosa, assessing its usefulness in reducing exacerbation 
frequency and its bactericidal effect, and comparing the results 
of sputum cultures at exacerbation with the prevalence of 
bacteria-related exacerbation before the treatment. Our results 
show that long-term intermittent dosing of azithromycin as 
addon therapy to conventional maximum triple therapy (long-
acting anticholinergics, long-term beta-agonists, and inhaled 
corticosteroids) reduces the number of AECOPD and hospital-
izations by more than a half, and also the days of hospital stay. 
The treatment was well tolerated over the 12-month period, and 
was stopped by only one patient due to dyspepsia.
Few studies focusing on the prophylactic use of antibiotics 
in COPD to prevent AECOPD have been published thus far, 
most of them examining long-term use of fluoroquinolones 
or macrolides. Sethi et al demonstrated that a 12-month 
regime with pulsed moxifloxacin 400 mg once a day for 
5 days every 8 weeks achieved a 25% reduction in AECOPD, 
and a larger reduction (45%) in patients who reported 
mucopurulent sputum at baseline. The authors concluded that 
pulsed moxifloxacin might be indicated in COPD patients 
with a high frequency of AECOPD, but excluded patients 
colonized by P . aeruginosa, one of the specific subgroups 
discussed in our study, because of the risk of development 
of resistant strains.25 Long-term macrolide therapy in COPD 
was also advocated in two published studies which analyzed 
erythromycin over a period of 12 months, with a significant 
reduction in the number and severity of AECOPD.13,14 In the 
first, Suzuki et al reported the results of a prospective random-
ized trial of erythromycin therapy 200–400 mg/day versus 
nonactive treatment for 12 months in 109 COPD patients 
Table 3 Microbiological evolution during long-term azithromycin therapy according to baseline groups and sputum culture isolates 
during AeCOPD
Year 1 
no azithromycin
n Year 2 azithromycin therapy
No AECOPD AECOPD with  
negative cultures
$1 AECOPD for  
common PPMs
$1 AECOPD  
for P. aeruginosa
Common PPM 7 1 3 2 1
P. aeruginosa colonization 9 2 2 0 5
Alternating PPM 4 1 0 0 3
Total (patients) 20 4 5 2 9
Abbreviations: AeCOPD, acute exacerbation of chronic obstructive pulmonary disease; PPM, potentially pathogenic microorganisms; P. aeruginosa, Pseudomonas aeruginosa.
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Figure 1 number of AeCOPD per patient before and after long-term azithromycin 
therapy. The continuous line represents group 1 patients with potentially pathogenic 
microorganisms and the discontinuous line represents group 2 patients with chronic 
bronchial colonization by Pseudomonas aeruginosa. 
Abbreviation: AeCOPD, acute exacerbation of chronic obstructive pulmonary 
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(average FEV1 1.4 L).13 They found a statistically significant 
increase in the relative risk of AECOPD in the control group 
versus the erythromycin group of 4.71 (95% CI, 1.53–14.5; 
P = 0.007) and more severe AECOPD in the control group 
than in the erythromycin group (P = 0.0007). In the second, 
a single-center, randomized, controlled trial, Seemungal et al 
administered erythromycin 250 mg twice daily or placebo for 
1 year to 109 patients with moderate to severe COPD (mean 
FEV1 50% of predicted).14 Erythromycin reduced AECOPD 
in relative terms by 35% and increased the median time to 
first exacerbation from 89 to 271 days, both differences being 
statistically significant.
Preliminary data from the prospective, placebo-controlled 
MACRO study in 1142 COPD patients randomized to receive 
azithromycin 250 mg or placebo daily for 1 year have been 
promising.15 Inclusion criteria were use of supplemental 
oxygen or treatment with systemic steroids for an AECOPD 
within the previous year. The frequency of AECOPD 
for those receiving azithromycin was lower at 1.4 versus 
1.8 patients/year (P = 0.004).
The microbiology data collected from the MACRO study 
have not yet been formally published.
Neither study assessed the impact of treatment in patients 
colonized by P . aeruginosa. Seemungal et al included patients 
with moderate to severe COPD in their series, of whom only 
35% had three or more AECOPD during the year prior to inclu-
sion. In the MACRO study, the frequency of AECOPD was also 
low. Our study enrolled an homogeneous population sample of 
severe or very severe COPD with very frequent AECOPD and 
patients with chronic colonization by P . aeruginosa.
Azithromycin offers clinical advantages over   erythromycin. 
Its metabolism does not interfere with the metabolic 
pathway of cytochrome P450, thus avoiding possible 
  metabolic interference with other drugs often used in 
COPD which share the same pathway, such as steroids and 
  theophylline. It has better gastrointestinal tolerance and less 
hepatotoxicity, and because it is not associated with long 
QT syndrome, is better tolerated and has a better safety 
profile in long-term use.26 Even though macrolides provide 
adequate coverage for the most frequent potentially patho-
genic microorganisms identified in AECOPD, their activity 
against H. influenzae differs. Azithromycin, the prototypical 
15-member ring macrolide, has greater bacteriological and 
clinical activity than 14-membered ring macrolides, such 
as erythromycin and clarithromycin.27 Interestingly, in our 
study, all strains of H. influenzae isolated prior to the initia-
tion of long-term azithromycin were resistant to erythromycin 
and 30% were resistant to clarithromycin, while none was 
resistant to azithromycin.
The subanalysis shows that Group 1, despite being the 
one with the highest number of AECOPD and hospitaliza-
tions prior to azithromycin therapy, demonstrated the greatest 
improvement with long-term azithromycin treatment, with 
highly significant reductions of around 70% in AECOPD 
and hospitalizations. The mechanism of improvement may 
be related to the antibacterial activity of azithromycin, par-
ticularly with regard to H. influenzae and M.   catarrhalis. 
AECOPD with isolates positive for these potentially patho-
genic microorganisms fell from 25 pre-azithromycin to 
just one (for H. influenzae) during long-term azithromycin 
therapy. However, we did not observe this level of bacterial 
eradication for S. pneumoniae, which has a higher prevalence 
of resistance to azithromycin, independently of the use of 
this antibiotic in the study.
We cannot exclude the possibility that the improve-
ment observed may be due in part to the anti-inflammatory 
and immunomodulatory properties of azithromycin.9 
  Azithromycin may decrease sputum volume and its viscoelas-
Table 4 Common microorganisms isolated in sputum culture during exacerbations before and after starting azithromycin and its 
antibiogram to macrolides
Year 1 
no AZT
Isolates pre-AZT Erythromycin Clarithromycin Azithromycin
Sen Int Res Sen Int Res Sen Int Res
H. influenzae 10 (31.3%) 0 0 10 7 2 1 10 0 0
S. pneumoniae 6 (18.8%) 3 0 3 3 0 3 3 0 3
M. catarrhalis 15 (50%) 14 1 1 15 0 1 15 0 0
Year 2 
AZT therapy
Isolates post AZT
H. influenzae 1 (20%) 0 0 1 0 0 1 0 0 1
S. pneumoniae 4 (80%) 0 0 4 0 0 4 0 0 4
M. catarrhalis 0 0 0 0 0 0 0 0 0 0
Abbreviations: AZT,  azithromycin;  H.  influenzae,  Haemophilus  influenzae;  S.  pneumoniae,  Streptococcus  pneumoniae;  M.  catarrhalis,  Moraxella  catarrhalis;  sen,  sensitive;   
InT, intermediate; res, resistant.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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ticity, and increase mucociliary transport.28 Azithromycin 
also accumulates in neutrophils, interfering with chemot-
axis to the inflammatory focus and promoting neutrophil 
apoptosis and clearance by macrophages.29 In their trial with 
long-term erythromycin, Seemungal et al analyzed inflam-
matory mediators in sputum (interleukin-6, interleukin-8, 
myeloperoxidase) and plasma (interleukin-6, interleukin-8, 
C-reactive protein) as secondary outcomes, but found no sta-
tistically significant treatment-related differences.14 The lack 
of effect of erythromycin on inflammatory markers suggests 
that the antimicrobial effects of macrolides in the treatment 
of COPD patients may be more important.
Patients with advanced COPD, especially those with 
repeated courses of antibiotic therapy or oral corticoster-
oids and requiring hospital admissions, have an increased 
risk of exacerbations caused by P . aeruginosa.30,31 In these 
patients, antibiotic treatment decisions should consider 
both the severity of AECOPD and the risk for isolation of 
P . aeruginosa.23
The fact that 45% of our patients had chronic bronchial 
colonization by P . aeruginosa (Group 2) reflects the severity 
of their COPD. In these patients, long-term azithromycin 
therapy also improved all the outcomes analyzed, achieving 
a statistically significant reduction of 43% in AECOPD. 
Hospitalizations and days of hospital stay also fell to 47% 
and 32%, respectively, in these patients, although these dif-
ferences did not reach statistical significance.
Macrolides, especially azithromycin, are useful in the 
treatment of chronic bronchial colonization by P . aeruginosa 
in patients with bronchiectasis, mainly in cases associated 
with cystic fibrosis.7,32 Azithromycin interferes with produc-
tion of virulence factors by P . aeruginosa, reduces biofilm 
formation by inhibiting alginate production, and decreases 
bacterial adherence.33 For these reasons, we think that long-
term azithromycin is especially indicated in these patients. 
However, the reductions in hospitalizations and days of mean 
hospital stay are less evident, possibly because they often 
require prolonged hospitalizations for parenteral antibiotic 
treatment, because P . aeruginosa is often resistant to oral 
antibiotics in this clinical situation.
Potential limitations of our study are the small number 
of patients included and the absence of a control group. 
However, our findings are very promising, especially for 
selected patients with severe COPD at high risk of exacerba-
tions despite conventional maximum treatment. This study 
may help in the design of future, randomized, controlled 
trials including more patients and assessing the impact 
of treatment in patients with different degrees of severity, 
focusing on aspects such as efficacy, safety, development of 
microbiological resistance, or economic burden.
In conclusion, we have shown that long-term intermittent 
azithromycin therapy, administered three times a week at a 
dosage of 500 mg, is well tolerated and associated with sig-
nificant reductions in AECOPD, number of hospitalizations, 
and days of hospital stay in patients with severe COPD and 
repeated AECOPD. This improvement is especially significant 
in patients with AECOPD associated with common potentially 
pathogenic microorganisms, possibly due to the antibacterial 
activity of the drug, and in patients with chronic bronchial colo-
nization by P . aeruginosa due to its ability to prevent AECOPD 
for common potentially pathogenic microorganisms also in 
these patients. These results suggest that long-term intermittent 
azithromycin therapy may be useful in the treatment of patients 
with severe COPD and frequent exacerbations.
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